2. Academic Validation
  3. Frenolicin B Targets Peroxiredoxin 1 and Glutaredoxin 3 to Trigger ROS/4E-BP1-Mediated Antitumor Effects

Frenolicin B Targets Peroxiredoxin 1 and Glutaredoxin 3 to Trigger ROS/4E-BP1-Mediated Antitumor Effects

  • Cell Chem Biol. 2019 Mar 21;26(3):366-377.e12. doi: 10.1016/j.chembiol.2018.11.013.
Qing Ye 1,  Yinan Zhang 2,  Yanan Cao 1,  Xiachang Wang 2,  Yubin Guo 1,  Jing Chen 3,  Jamie Horn 4,  Larissa V Ponomareva 4,  Luksana Chaiswing 5,  Khaled A Shaaban 4,  Qiou Wei 5,  Bradley D Anderson 6,  Daret K St Clair 5,  Haining Zhu 3,  Markos Leggas 6,  Jon S Thorson 7,  Qing-Bai She 8
Affiliations

Affiliations

  • 1 Department of Pharmacology and Nutritional Sciences, College of Medicine, University of Kentucky, Lexington, KY 40536, USA; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
  • 2 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA; Center for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY 40536, USA; Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210047, China.
  • 3 Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA; Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536, USA.
  • 4 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA; Center for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY 40536, USA.
  • 5 Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA; Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, KY 40536, USA.
  • 6 Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA; Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA; Center for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY 40536, USA.
  • 7 Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA; Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA; Center for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY 40536, USA. Electronic address: jsthorson@uky.edu.
  • 8 Department of Pharmacology and Nutritional Sciences, College of Medicine, University of Kentucky, Lexington, KY 40536, USA; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA. Electronic address: qing-bai.she@uky.edu.
PMID: 30661989 DOI: 10.1016/j.chembiol.2018.11.013
Abstract

Peroxiredoxin 1 (Prx1) and glutaredoxin 3 (Grx3) are two major antioxidant proteins that play a critical role in maintaining redox homeostasis for tumor progression. Here, we identify the prototypical pyranonaphthoquinone natural product frenolicin B (FB) as a selective inhibitor of Prx1 and Grx3 through covalent modification of active-site cysteines. FB-targeted inhibition of Prx1 and Grx3 results in a decrease in cellular glutathione levels, an increase of Reactive Oxygen Species (ROS), and concomitant inhibition of Cancer cell growth, largely by activating the peroxisome-bound tuberous sclerosis complex to inhibit mTORC1/4E-BP1 signaling axis. FB structure-activity relationship studies reveal a positive correlation between inhibition of 4E-BP1 phosphorylation, ROS-mediated Cancer cell cytotoxicity, and suppression of tumor growth in vivo. These findings establish FB as the most potent Prx1/Grx3 inhibitor reported to date and also notably highlight 4E-BP1 phosphorylation status as a potential predictive marker in response to ROS-based therapies in Cancer.

Keywords

4E-BP1; AKT; RAS; ROS; eIF4E; frenolicin B; glutaredoxin 3; mTORC1; peroxiredoxin 1; pyranonaphthoquinone.

Figures
Products